I wonder whether the Rotec deal towards charging points is a step in the wrong direction? I hope not all eggs are in this particular basket. I have an impression that battery powered electric cars will be a passing phase on the way to hydrogen powered vehicles with fuel cells powered by hydrogen/oxygen. AFC should be aiming to get into this market.
Is it stated anywhere for how long d2p is active? The brochure mentioned by Ox042 mentions 'long periods' While this is not important for disposables, other areas such as plastic surfaces it probably matters as a selling point. Anyway, what a good day.
PKOK, in what way is this an admission of failure to meet FDA submission objectives? Which is the 'hidden away' paragraph to which you refer?. Can you clarify what you mean in your second sentence, please, as it is incomprensible at present. Thanks.
There has been some discussion about AGL being taken out by a big beast , perhaps after FDA approval. My take, supported by todays RNS is that AGL wants to, and probably can remain independent. The idea of an independent lab owned by AGLextracting CTS for trials performed by others and researching better ways to culture CTS suggests to me AGL becoming a powerful player in the cancer world, rather than just a seller of a very clever simple mousetrap. It is of course possible for someone to offer a crazy price, but that price is going to go increase with every development by AGL. We will see.
This is just one of a long string of brilliant RNS, each of which flicks the SP up for a few days, and then back to square one - or nearly. The big sustained rise will surely only come when FDA approves the present submission for breast cancer, and this submission is, I understand, inextricably linked to the results of the downstream genetic analysis. What I am uncertain about is how easy will it then be for the Parsortix mousetrap to gain FDA approval to be used for other cancers, lymphomas, and, for that matter, the analysis of foetal red cells for diagnosing inherited foetal abnormalities, Downs syndrome et al, ? Does anyone on the board have an insight into FDA procedure in this?
Production companies seem more interested in shock / horror revelations (in all spheres of activity), than in solutions. They are less interested in demonstrating solutions - it is not, in their view - good TV
Yellowf1. Agreed, presentational skills are very poor and this is no help to PHE or its long suffering PIs. Someone needs to give him a few tips, including not having over-reliance on the dreaded Powerpoint.
Geovanni. The paper you cite gives a useful insight into the complexities of approval by FDA. Thank you for citing it. The Parsortix device is inextricably linked to the subsequent use of the isolated cancer cell, both the subsequent genetic or other testing , and the intended therapeutic /treatment activity that follows. I suspect there will be no problem for the FDA with the isolation of CDCs using Parsortix, but there is potential for problems arising from the validity of the subsequent investigations performed on the cell contents, etc in determining treatment.
Oxygen is essential to the process of oxobiodegradation.The rate of degradation is presumably determined by the pO2 in some way. So in buried material, or at the bottom of the sea, where pO2 is very low, degradation will be very slow. Think of leaves buried at the bottom of a compost heap, (or a fossilised leaf) They do not decompose. The point I am making is that there will always be some circumstances in which oxobiodegradation does not work as well as where there is plenty of oxygen, and these examples can be used by detractors, competitors, or mad professors etc,.
An oxobiodegradable bag will not break down buried in soil where the oxygen saturation is near zero. A no brainer. I think SYM is unlikely to make £££ from this technology, and is more likely to make money from its other products.
This bit of kit, wondrous in its simplicity, is leading to the certain extinction of the hit and miss methods of extracting cancer DNA from whole blood. There was a long article in the Times puffing this process earlier in the week, and I guess a large number of researchers have built their career on it. Time to retire, and let Parsortix do an infinitely better job.
When AGL gets FDA approval, as I understand it, this will be specifically for application to breast cancer, and that further submissions have to be made for use in other malignancies, eg prostate, lung, bowel lymphoma etc,. Am I right, or is this FDA approval generic? in reference to ennombrede, I think that it is unlikely that Parsortix will have a place in health MOTs, as Parsortix picks up circulating tumour cells, which implies metastatic disease, and thus will not pick up primary tumours that have yet to metastasise.
Cabby Could the recent SP move, which was sustained during this last week and which was finished off with an 8% rise yesterday, be a hint that there is someone stalking AGL while, as you suggest, the price is not too high? it could . of course, just be that folk are beginning to realise that this simple bit of kit is a complete winner. I hope it is not taken out as I think there is far more in it for PIs if it stays independent. It is worth remembering that there are a number of very big players who have made links with AGL (can't remember all names just now; but including Abbott, Quiagen, Phillips) who would be reluctant to see their relationship shift from one with AGL to one with another large pharma company that takes over AGL. Happy days!